申请人:Lonza Ltd.
公开号:US05352801A1
公开(公告)日:1994-10-04
Starting from 5-alkylidene or 5-benzylidenetetramic acid optically-active 4-amino-3-hydroxy-carboxylic acids are produced in the (rel-3R,4R) configuration, especially statine. The synthesis process includes the O-acylation of the tetramic acid to the corresponding 4-acyloxy-3-pyrrolin-2-one, a stereoselective hydrogenation to (rel-4R,5R)-4-acyloxy-5-alkyl or 5-benzylpyrrolidin-2-one and an enantioselective enzymatic hydrolysis of the (4R,5R)-enantiomer to the corresponding 4-hydroxypyrrolidin-2-one. The nonhydrolyzed enantiomer is separated and converted into the target compound with (3S,4S) configuration by hydrolytic cleavage of the lactam ring and the ester function and optionally introduction of an amino protective group. Analogously the (3R,4R)-enantiomer can be obtained from the 4-hydroxypyrrolidin-2-one from the enzymatic hydrolysis. The 4-amino-3-hydroxycarboxylic acids producible according to the invention are the structural elements of enzyme inhibitors.
从5-烷基亚甲基或5-苯甲亚甲基四元酸开始,可以制备光学活性的4-氨基-3-羟基-羧酸,特别是statine(一种氨基酸)。合成过程包括将四元酸进行O-酰化,得到相应的4-酰氧基-3-吡咯烷-2-酮,进行立体选择性氢化,得到(rel-4R,5R)-4-酰氧基-5-烷基或5-苯甲基吡咯烷-2-酮,然后进行对映选择性的酶解,得到相应的4-羟基吡咯烷-2-酮。未酶解的对映体被分离并通过内酰胺环和酯功能的水解裂解,并可选择性地引入氨基保护基,转化为具有(3S,4S)构型的目标化合物。类似地,(3R,4R)-对映体可以从酶解的4-羟基吡咯烷-2-酮中获得。根据本发明可制备的4-氨基-3-羟基羧酸是酶抑制剂的结构元素。